{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:46:24Z","timestamp":1793778384846,"version":"4.6.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jhepr.2025.101516","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T21:58:04Z","timestamp":1752616684000},"page":"101516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4086-7955","authenticated-orcid":false,"given":"Edward","family":"Gane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5406-4603","authenticated-orcid":false,"given":"Ewa","family":"Janczewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7658-7130","authenticated-orcid":false,"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2376-421X","authenticated-orcid":false,"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9030-6086","authenticated-orcid":false,"given":"Cheng-Yuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8028-8849","authenticated-orcid":false,"given":"Maria","family":"Hlebowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Asahina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5073-2678","authenticated-orcid":false,"given":"Ting-Tsung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Kalmeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Jezorwski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2036-8113","authenticated-orcid":false,"given":"Gloria","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3813-7769","authenticated-orcid":false,"given":"Zacharias","family":"Anastasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6857-2572","authenticated-orcid":false,"given":"Thomas N.","family":"Kakuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8627-400X","authenticated-orcid":false,"given":"Thierry","family":"Verbinnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nonko","family":"Pehlivanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bakala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6993-8206","authenticated-orcid":false,"given":"Michael","family":"Biermer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2025.101516_bib1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101516_bib2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101516_bib3","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"66","author":"Lok","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101516_bib4","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jhep.2022.07.010","article-title":"Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB","volume":"77","author":"Yuen","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101516_bib5","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41575-022-00700-z","article-title":"Nomenclature of HBV core protein-targeting antivirals","volume":"19","author":"Zoulim","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101516_bib6","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02439-19","article-title":"Antiviral properties and mechanism of action studies of the hepatitis B virus capsid assembly modulator JNJ-56136379","volume":"64","author":"Berke","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhepr.2025.101516_bib7","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1136\/gutjnl-2022-328041","article-title":"Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection","volume":"72","author":"Janssen","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2025.101516_bib8","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/jac\/dkaa179","article-title":"Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136379 across full-length genotype A-H clinical isolates and core site-directed mutants in vitro","volume":"75","author":"Verbinnen","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jhepr.2025.101516_bib9","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2020.04.036","article-title":"JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection","volume":"159","author":"Zoulim","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101516_bib10","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S2468-1253(23)00148-6","volume":"8","author":"Yuen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101516_bib11","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jhep.2024.03.046","article-title":"JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analog suppressed patients with chronic hepatitis B: REEF-2","volume":"81","author":"Agarwal","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101516_bib12","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/935295","article-title":"Hepatitis B surface antigen could contribute to the immunopathogenesis of hepatitis B virus infection","volume":"2013","author":"Kondo","year":"2013","journal-title":"ISRN Gastroenterol"},{"key":"10.1016\/j.jhepr.2025.101516_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tim.2017.07.006","article-title":"Mechanisms of hepatitis B virus persistence","volume":"26","author":"Tsai","year":"2018","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.jhepr.2025.101516_bib14","article-title":"Immune mechanisms underlying hepatitis B surface antigen seroclearance in chronic hepatitis B patients with viral coinfection","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2025.101516_bib15","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3390\/vaccines11121825","article-title":"Sustained liver HBsAg loss and clonal T- and B-cell expansion upon therapeutic DNA vaccination require low HBsAg levels","volume":"11","author":"Conceicao-Neto","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.jhepr.2025.101516_bib16","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1053\/j.gastro.2020.01.032","article-title":"Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice","volume":"158","author":"Michler","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101516_bib17","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0168-8278(24)00432-X","article-title":"GS-008 the combination of therapeutic vaccination with siRNA-mediated silencing of HBV and PD-L1 effectively breaks HBV-specific immunotolerance in high-titer HBV carrier mice","volume":"80","author":"Kosinska","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101516_bib18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhepr.2025.101516_bib19","series-title":"VIR-2218 and VIR-3434 with or without pegylated interferon alfa-2a for the treatment of chronic HBV infection: end of treatment (EOT) results after 24 weeks of therapy (MARCH study part B)","author":"Gane","year":"2025"},{"key":"10.1016\/j.jhepr.2025.101516_bib20","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jhep.2024.08.010","article-title":"Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B","volume":"82","author":"Buti","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101516_bib21","series-title":"Presented at the American association for the study of the liver (AASLD) - the liver Meeting\u00ae; november 10-14","author":"Kennedy","year":"2023"},{"key":"10.1016\/j.jhepr.2025.101516_bib22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1083\/jcb.107.1.321","article-title":"Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells","volume":"107","author":"Dustin","year":"1988","journal-title":"J Cell Biol"},{"key":"10.1016\/j.jhepr.2025.101516_bib23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF01714980","article-title":"Acute hematologic effects of interferon alpha, interferon gamma, tumor necrosis factor alpha and interleukin 2","volume":"62","author":"Aulitzky","year":"1991","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jhepr.2025.101516_bib24","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1002\/hep.22956","article-title":"Benefits and risks of interferon therapy for hepatitis B","volume":"49","author":"Perrillo","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101516_bib25","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/apt.13779","article-title":"Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B","volume":"44","author":"Marcellin","year":"2016","journal-title":"Aliment Pharmacol Ther"}],"updated-by":[{"DOI":"10.1016\/j.jhepr.2025.101662","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000}},{"DOI":"10.1016\/j.jhepr.2025.101662","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000}}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925001946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925001946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:21:04Z","timestamp":1777634464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555925001946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2589555925001946"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101516","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101516","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101516"}}